首頁 › 膀胱癌 › 俄克拉荷馬州 › Oklahoma City
Oklahoma City, OK 的 膀胱癌 臨床試驗
11 項針對 膀胱癌 的研究正在 Oklahoma City（約 30 英里範圍內）及其周邊地點尋找參與者。開啟研究以查看參與資格及聯絡研究團隊的方式。
官方研究文本（英文）
正在為研究招募對象嗎？將此頁面置頂展示 — $99 / 30 天 →
The Vanguard Study: Testing a New Way to Screen for Cancer
招募中歡迎健康志工
- University of Oklahoma Health Sciences Center, Oklahoma City
Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial
招募中2 期
- University of Oklahoma Health Sciences Center, Oklahoma City
Testing the Addition of an Anti-Cancer Drug, Gemcitabine, to Usual Treatment (BCG Alone) in People Whose Non-Muscle Invasive Bladder Cancer (NMIBC) Came Back After Prior BCG Therapy
招募中3 期
- University of Oklahoma Health Sciences Center, Oklahoma City
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
招募中觀察性研究歡迎健康志工
- Mercy Hospital Oklahoma City, Oklahoma City
Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial
招募中2 期
- University of Oklahoma Health Sciences Center, Oklahoma City
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
招募中2 期
- University of Oklahoma Health Sciences Center, Oklahoma City
FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3
招募中1 期
- University of Oklahoma - Health Sciences Center, Oklahoma City
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study
招募中3 期
- University of Oklahoma Health Sciences Center, Oklahoma City
- Mercy Hospital Oklahoma City, Oklahoma City
A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2
招募中2 期
- OU Health Stephenson Cancer Center, Oklahoma City
- OU Medical Center, Oklahoma City
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
招募中1 期
- OU Health University of Oklahoma Medical Center, Oklahoma City
- Stephenson Cancer Center (chemo location), Oklahoma City
- University of Oklahoma Health Science Center, Oklahoma City
Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies (ELEPHAS-05)
招募中觀察性研究
- Mercy Hospital - OKC, Oklahoma City
其他城市的 膀胱癌 試驗
- New York City, NY35 項研究
- Nashville, TN31 項研究
- Houston, TX31 項研究
- Dallas, TX27 項研究
- Washington, DC26 項研究
- Boston, MA26 項研究
- Baltimore, MD24 項研究
- Los Angeles, CA24 項研究
- St. Louis, MO22 項研究
- Seattle, WA21 項研究
- Chicago, IL21 項研究
- Philadelphia, PA21 項研究
Oklahoma City 的其他研究
- 非小細胞肺癌28 項研究
- 卵巢癌28 項研究
- 子宮內膜癌25 項研究
- 大腸直腸癌22 項研究
- 前列腺癌21 項研究
- 肺癌19 項研究
- 乳癌17 項研究
- 轉移性癌症16 項研究
- 癌症（所有類型）14 項研究
- 急性髓系白血病14 項研究
- 頭頸部鱗狀細胞癌13 項研究
- 胰臟癌11 項研究
資料來源：ClinicalTrials.gov，擷取日期 2026年10月6日。各研究自行設定資格標準；由研究團隊決定參與者資格。